| Document |
Document Title |
|
WO/2016/011501A1 |
A fusion protein comprising an N-terminal portion and a C-terminal portion, wherein the N-terminal portion is a heterologous protein of interest which includes membrane proteins and antigens and the C-terminal portion is a polyhedrin tar...
|
|
WO/2016/002717A1 |
Provided is a bone formation promoter having high biological safety with which it is possible to promote bone formation. The bone formation promoter of the present invention includes a self-assembling peptide capable of forming a β-shee...
|
|
WO/2015/196167A1 |
The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.
|
|
WO/2015/195904A1 |
The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the ...
|
|
WO/2015/196089A1 |
The present disclosure provides anti-CD22 antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.
|
|
WO/2015/195796A1 |
An antimicrobial composition compatible with anionic compounds is prepared by a process of contacting a cationic peptide-based antimicrobial extract with an ion exchange resin.
|
|
WO/2015/190555A1 |
The present invention provides a synthetic peptide whereby antibodies to an autoantigen can be derived, and specifically provides: a multiplex alloantigenic peptide including a dendritic core and a B-cell-recognition peptide, the multipl...
|
|
WO/2015/190849A1 |
The present invention provides a melittin-polyethylene glycol conjugate in which polyethylene glycol is coupled to an N-terminal amino group of melittin, a method of manufacturing the same, and a pharmaceutical composition for treatment ...
|
|
WO/2015/187359A1 |
The present disclosure provides a composition comprising an agent that modulates binding of Vista to LRIG1; and further provides methods of modulating binding of Vista to LRIG1. The present disclosure provides a composition comprising an...
|
|
WO/2015/179947A1 |
A method for assessing cell contraction includes adhering contractile cells to an oxidized and cellular adhesion activated surface of a biocompatible silicone elastomer film. The biocompatible silicone elastomer film allows the cells to ...
|
|
WO/2015/181491A1 |
The invention relates especially to a method for grafting oligopeptides into porous hybrid materials, especially metal-organic frameworks (MOFs). The invention also relates to porous hybrid materials functionalised on the outer surface a...
|
|
WO/2015/173824A1 |
A polyplex of a double stranded RNA and a polymeric conjugate is provided, wherein the polymeric conjugate consists of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties, each PEG moiety being ...
|
|
WO/2015/163818A1 |
The present invention is directed to enzymes having Asx-specific ligase and cyclase activity and to nucleic acids encoding those as well as methods of the manufacture of said enzymes. Further encompassed are methods and uses of these enz...
|
|
WO/2015/162093A1 |
A solid substrate for the extraction, stabilization, and storage of proteins is provided. The substrate includes: a polysaccharide, such as melezitose under a substantially dry state. The substrate is configured to extract proteins from ...
|
|
WO/2015/149188A1 |
Disclosed herein are multifunctional nanoparticle compositions. The compositions can be useful for the treatment of cancer by enhancing the anti-tumor effectiveness of radiation directed to a tissue, cell or a tumor and the methods of us...
|
|
WO/2015/150243A1 |
The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at ...
|
|
WO/2015/135069A1 |
Self-supporting or supported porous carbon films, including nanoporous carbon films, are provided. The porous carbon films comprise an open network of interconnected pores. Methods for making porous carbon films are also provided. One sy...
|
|
WO/2015/131257A1 |
The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endo...
|
|
WO/2015/131258A1 |
The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endo...
|
|
WO/2015/132350A1 |
The present invention relates to the immobilization of biomolecules on a non- functionalized carrier by irradiating the biomolecule-impregnated carrier with a light of a wavelength of at least 340 nm.
|
|
WO/2015/128643A1 |
The invention relates to an antimicrobial surface, in particular a surface functionalised with a peptide comprising an antimicrobial moiety. The invention comprises a surface functionalised with a peptide comprising an antimicrobial moie...
|
|
WO/2015/124767A1 |
The present invention first relates to a bi-functional peptide characterized in that it comprises a metal-binding peptide (MBP) domain and a cell-specific peptide (CSP) domain, wherein said MBP and CSP domains are linked by a linker. A b...
|
|
WO/2015/123756A1 |
This invention provides compound having a structure of Formulas: Furthermore, methods and uses of such compounds for covalently bonding to a sugar acceptor, to form modified protein therapeutics having reduced enzymatic hydrolysis, impro...
|
|
WO/2015/120548A1 |
Genetically encoded, photocleavable proteins are derived from a fluorescent protein. Upon illumination, the proteins photocleave and spontaneously dissociate into two or more fragments or release one end of an internal loop.
|
|
WO/2015/121526A1 |
The invention relates to a peptide, to a magnetic peptide, and to a method for detecting celiac disease. The invention also relates to a deamidated peptide used to produce said magnetic peptide, and to the use of both for the detection o...
|
|
WO/2015/120187A1 |
Disclosed are binding proteins, or fragments thereof, that specifically binds to a cancer- specific glycosylation variant of a protein and to a second epitope on the same protein, to a different protein presented on the same cell, or to ...
|
|
WO/2015/118152A1 |
The present invention relates to a method of reversibly binding polypeptides to a solid phase comprising a hydrophilic surface, preferably for the use in mass spectrometry based proteomics, Kits providing reagents for the method of the i...
|
|
WO/2015/103782A1 |
Provided are a stable FGF21 mutant, fusion polypeptide and conjugate comprising the mutant, as well as a use of the mutant in the preparation of medicaments for treating metabolic disorders. The mutant comprises only one amino acid subst...
|
|
WO/2015/103028A1 |
A multicomponent nanomaterial AuNP(DTDTPA)(Ga), where DTDTPA is an amino-carboxylate ligand (diethylene triamine pentaacetic acid, DTPA) linked to the surface of the Au nanoparticle (NP) via dithiol (DT) linkage. Another embodiment is a ...
|
|
WO/2015/095952A1 |
VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.
|
|
WO/2015/091046A1 |
Disclosed is a method for immobilizing proteins on a carrier, characterized in that the protein is incubated with the carrier in an aqueous phase in a discontinuous contact vacuum mixer dryer and in that the immobilized protein is then i...
|
|
WO/2015/069777A1 |
This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjec...
|
|
WO/2015/057004A1 |
The present invention relates to: a metalloprotein-insoluble carrier for adsorbing a metalloprotein in an insoluble carrier to stabilize the metalloprotein and maintaining the catalytic activity of a metalloprotein for a long time by cro...
|
|
WO/2015/054778A1 |
The invention relates to traceable metallic products, methods of uses and methods of making same. The metallic products may be made traceable for integrity purposes, identification purposes, counterfeit avoidance and the like. The invent...
|
|
WO/2015/057803A1 |
Deubiquitinating enzyme (DUB) probes are provided that resemble native diubiquitin (diUB) with a similar linkage size and that may contain a Michael acceptor for trapping the DUB active-site cysteine. For example, both K63- and K48-linke...
|
|
WO/2015/053353A1 |
Provided is a peptide that specifically binds to IgY. A peptide characterized by: containing an amino acid sequence that consists of 17 amino acid residues and is represented by a formula: (X1-3)-C-(X5)-W-(X7-11)-W-(X13)-C-(X15-17) [wher...
|
|
WO/2015/054587A1 |
The invention provides methods and compositions for a mutein aminoacyl-tRNA synthetase that preferentially charges a tRNA with a non-natural amino acid. Also provided are methods for incorporating the non-natural amino acid, para-methyla...
|
|
WO/2015/050199A2 |
[Problem] To provide a heretofore completely different and novel peptide synthesis technique, and to provide a novel compound that enables the synthesis/creation of a novel artificial functional protein and the synthesis/creation of a no...
|
|
WO/2015/038662A1 |
The present disclosure provides methods and compositions related to the cytosolic delivery of proteins and cell-impermeable small molecules into live cells using an endosomolytic dimer of cell-penetrating peptide TAT.
|
|
WO/2015/035474A1 |
The present specification teaches a serological test for Mycoplasma and the development of prophylactic and therapeutic compositions to treat ruminant subjects infected with or potentially exposed to Mycoplasma species.
|
|
WO/2015/035405A1 |
Disclosed are methods of treating or modulating protein energy wasting (PEW) in an ESRD patient by administration of a myostatin antagonist.
|
|
WO/2015/034000A1 |
[Problem] To provide: a multimer of an immunoglobin-binding protein, that has improved characteristics as an affinity ligand for affinity chromatography; and an insoluble carrier comprising said multimer that has been immobilized. [Solut...
|
|
WO/2015/035010A1 |
The present invention relates generally to vaccines for drug addiction. In particular, the present disclosure provides adjuvants for significantly improving immune responses generated against addictive drug haptens.
|
|
WO/2015/034915A1 |
A method of improving protein functionality includes obtaining a protein such as protein contained within exclusion bodies contained within bacteria or yeast used for the recombinant expression of the protein. The exclusion bodies are so...
|
|
WO/2015/030094A1 |
The purpose of the present invention is to provide: a Fab region-binding peptide having an excellent capacity for binding to a Fab region of IgG; an affinity separation matrix having the peptide as a ligand; and a method for producing a ...
|
|
WO/2015/029714A1 |
Provided is a production method for a protein array or a peptide array, the method being suitable for efficient screening of functional proteins or functional peptides. The production method for a protein array or a peptide array of the ...
|
|
WO/2015/026892A1 |
The present invention is directed to sequence-optimized CD 123 x CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignanc...
|
|
WO/2015/021509A1 |
This invention resides in using metal complex-activated particles to bind molecules, polymers and other particles to each other, so as to produce multifunctional conjugates having controlled ratios of two or more different molecules.
|
|
WO/2015/020159A1 |
The present invention pertains to a method for manufacturing a protein, the method being provided with an inspection process including: a step for approximating, to one or more normal distributions, a protein-derived infrared absorption ...
|
|
WO/2015/003622A1 |
Provided are a composite carrier for immobilization of a protein, polypeptide or oligopeptide, a preparation method and an application thereof. The composite carrier is a porous material which comprises: (1) a porous organic foam materia...
|
